Home
overview

 SMi is proud to present the New Ophthalmic Drugs Focus Day  - Novel Drug Delivery Through a Complex Barrier

Introducing the only ophthalmic conference to hold a full day exploring alternatives to intravitreal delivery to the posterior segment of the eye. With the global ophthalmic drug market currently valued at $17,364 million USD, this focus day will asses the growing need for research and development of novel delivery approaches to expand the current ophthalmic delivery methods in today's market.

In conjunction with Europe’s leading Ophthalmic Drugs conference, we will explore new discoveries in novel drug delivery through case studies, regulatory outlooks and industry examples to give a comprehensive overview of the Ophthalmic Drug Delivery space.

This focus day offers you peer-to-peer networking with Global Product Managers, Heads of Drug Development, Senior Directors of Ophthalmology, Heads of Research and Development and many more.

We look forward to welcoming you to the conference in November.
 

Early registration is strongly advised to avoid disappointment.

 

 

  • Learn how leaders in big Pharma and research are unveiling innovations in ophthalmic drug delivery 
  • Explore novel approaches to delivery of ocular drugs including: the use of stimuli-responsive hydrogels, thermally induced phase separation, lenses and implants
  • Network with the leading pharmaceutical and biotech companies developing novel delivery methods 


 

 Key Job Titles:

Chief, Vice Presidents, Heads, Senior Directors, Directors, Principals, Principal Scientists, Team/ Project Leaders, Clinicians, Clinical Trial Managers, Medical Officers of:

Ophthalmology
Ophthalmic devices
Drug Delivery
Drug discovery
Research and development
Clinical development
Quality assurance
Immunology, Inflammation and Allergies
Market Access
Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.


 

Aerie Pharmaceuticals; Aero Pump Gmbh; Alimera Sciences; Alimera Sciences Limited; Allergan Ltd; Annexin Pharmaceuticals AB; Biozep AS; Boehringer Ingelheim Pharma GmbH & Co. KG; Casebia Therapeutics; Elasmogen Ltd; Experimentica Ltd; Gyroscope Therapeutics ; Janssen R&D, JNJ; King khaled eye specialist hospital ; Kingston University; LABORATOIRES THEA; Medicines and Healthcare Products Regulatory Agency; Medivis; Medpharm; MeiraGTx; MHRA; Nanoptima Ltd; NEMERA; NightstarX; Novartis Pharma Schweiz Ag; Optceutics Limited; Ora Europe Ltd; Oxstem; Queens University Belfast; Roche; Roche Products Ltd; Roechling; RXGen; Santen Incorporated; Silgan Dispensing; Similasan; Similasan AG; Spark Therapeutics; Topivert; Topivert Ltd; TwoXAR; University of Oxford; West Pharmaceutical Services;
 

Workshop programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Peter Morgan Warren

Peter Morgan Warren, Medical Assessor, MHRA
View Bio

9:10 Safety and Efficacy of a Novel Intracapsular Drug Delivery Platform

Michael Burr

Michael Burr, Vice President of Product Development, iVeena
View Bio

  • iVeena has developed an intracapsular drug delivery platform that enables bi-directional drug delivery to anterior and posterior eye segments.
  • The initial platform technology application is IVMED-20, a bioerodible dexamethasone delivery implant placed during cataract surgery to prophylax cystoid macular edema, as well as, control inflammation and pain from the procedure.
  • IVMED-20 is intended for cataract patients at high risk of developing cystoid macular edema, including concurrent: diabetic retinopathies & edemas, epiretinal membranes, macular hole, retinal vein occlusions, and uveitis.
  • IVMED-20 has been studied in an ex-US clinical study. This proof of concept study, albeit not statistically powered, suggest the ability to safely control inflammation, and reduce retinal thickening, without anti-inflammatory eye drops.
  • 9:50 Novel Delivery for the treatment of Glaucoma – a case study

    Simon Chandler

    Simon Chandler, Executive Director, Clinical Development, Allergan Ltd

  • Durysta: an implant for IOP control in Glaucoma
  • The Clinical Development of Durysta – Phase 1/2 data
  • Phase 3 outcomes and results

     

  • 10:30 Morning Coffee

    11:00 Barriers to Posterior Segment Drug Delivery

    Clive  G Wilson

    Clive G Wilson, Research Professor, University of Strathclyde
    View Bio

  • New drugs offer the promise of stopping or even reversing age-related sight impairment but need appropriate methods of delivery.
  • Overview of the key issues in systemic or topical administration of drugs for the back of the eye
  • Understand how the ageing eye alters drug distribution from a reservoir.
  • Examine tactical approaches to overcoming barrier issues and examine advantages and shortfalls of approaches.
  • 11:40 Drug delivery to the posterior segment of the eye

  • Novel delivery methods that are currently in the pipeline
  • What are the main challenges in delivery to the back of the eye?
  • How will we tackle these challenges and learn from recent R&D?
     
  • Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA
    View Bio

    Clive  G Wilson

    Clive G Wilson, Research Professor, University of Strathclyde
    View Bio

    Virginia Calder

    Virginia Calder, Reader in Ocular Immunology, UCL Institute of Ophthalmology
    View Bio

    Mitchell De Long

    Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    12:20 Networking Lunch

    13:20 Regulatory perspectives on novel ocular drug delivery

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA
    View Bio

  • Novel ocular drug delivery and the regulatory framework – clinical considerations
  • Combination products, devices and borderline products
     
  • 13:50 Sustained drug release for managing ocular hypertension and glaucoma

    Jinzhong Zhang

    Jinzhong Zhang, Vice President, Graybug Vision Inc
    View Bio

  • Long-lasting therapeutics that effectively lower and maintain IOP remain a substantial unmet medical need
  • Available ocular drug delivery platforms
  • Choice of administration routes: intracameral, subconjunctival or intravitreal injection
  • An injectable formulation of a beta-adrenergic antagonist prodrug for sustained reduction of intraocular pressure
     
  • 14:30 Afternoon Tea

    15:00 Age-related eye diseases: how can drug delivery research help?

    Raid Alany

    Raid Alany, Chair in Pharmaceutical Formulation and Drug Delivery, Kingston University
    View Bio

  • Delivery of drugs and biologics to the front and back of the eye is a challenge
  • Dry eye, glaucoma and AMD are prevalent amongst the aging population; they require pharmaceutical intervention using drug(s) that need to be formulated
  • Novel pharmaceutical formulation and drug delivery strategies could offer solutions to unmet ophthalmic needs
  • 15:40 An update on ocular drug delivery pathways: from cornea to retina

    Borja Salvador Culla

    Borja Salvador Culla, Anterior Segment, Cornea and Refractive surgery consultant in Ophthalmology, Centro de Oftamologia Barraquer
    View Bio

  • Difficulties in delivering therapeutical levels of medication to the eye
  • Current pathways of drug delivery to the eye
  • New drug delivery devices: contact lenses, intravitreal implants, depot…
  • What will the future bring us?
     
  • 16:20 Chairman’s Closing Remarks and Close of Day One

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA
    View Bio

    +

    FEATURED SPEAKERS

    Borja Salvador Culla

    Borja Salvador Culla

    Anterior Segment, Cornea and Refractive surgery consultant in Ophthalmology, Centro de Oftamologia Barraquer
    Clive  G Wilson

    Clive G Wilson

    Research Professor, University of Strathclyde
    Jinzhong Zhang

    Jinzhong Zhang

    Vice President, Graybug Vision Inc
    Michael Burr

    Michael Burr

    Vice President of Product Development, iVeena
    Mitchell De Long

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Peter Morgan Warren

    Peter Morgan Warren

    Medical Assessor, MHRA
    Raid Alany

    Raid Alany

    Chair in Pharmaceutical Formulation and Drug Delivery, Kingston University
    Simon Chandler

    Simon Chandler

    Executive Director, Clinical Development, Allergan Ltd
    Virginia Calder

    Virginia Calder

    Reader in Ocular Immunology, UCL Institute of Ophthalmology

    Borja Salvador Culla

    Anterior Segment, Cornea and Refractive surgery consultant in Ophthalmology, Centro de Oftamologia Barraquer
    Borja Salvador Culla

    - 1997-2004: Degree in Medicine and General Surgery at Universitat Autònoma de Barcelona
    - 2004-2009: Residency training in Ophthalmology at Centro de Oftalmología Barraquer
    - 2010-2015: Two simultaneous Clinical Research Fellowships, at “Boston Kpro group” (Massachusetts Eye & Ear Infirmary, HMS, Boston) and at “Kohane Lab for Biomaterials and Drug delivery” (Boston Children’s Hospital, HMS, and Langer Lab, Koch Institute, MIT, Boston)
    - 2015-2016: Clinical Fellowship in “Cornea, External Eye Diseases and Cataract Surgery” at Royal Victoria Infirmary (Newcastle Upon Tyne, UK)
    - 2016-2018: Clinical Fellowship in Refractive Surgery at Centro de Oftalmología Barraquer
    - 2018-to date: Consultant in Anterior Segment, Cornea and Refractive Surgery at Centro de Oftalmología Barraquer
     

    Clive G Wilson

    Research Professor, University of Strathclyde
    Clive  G Wilson

    Clive Wilson is a Research Professor at Strathclyde University. With colleagues at Nottingham University, he pioneered scintigraphy in the study of drug absorption. At Strathclyde, his research covers projects on ocular devices, oral bioavailability, and wound-healing. As CSO of Re-Vana, from Queen’s University Belfast , he works on the microfabrication of ocular implants. He has published more than 190 papers, 7 books and over 100 reviews. He is a Fellow of the Controlled Release Society and an Eminent Fellow of the Academy of Pharmaceutical Sciences. In November 2017, he was awarded doctor honoris causa of Semmelweis University, Budapest, Hungary.

    Jinzhong Zhang

    Vice President, Graybug Vision Inc
    Jinzhong Zhang

    Dr. Zhang has over 20 years of experience in research and drug development including more than a decade working at two global ophthalmic pharmaceutical companies, Bausch + Lomb and Santen Pharmaceutical, with increasing responsibility. He is the Vice President of Preclinical Development at Graybug Vision since December 2017. Dr. Zhang was Assistant Professor of Ophthalmology and has authored more than 50 peer-reviewed papers. He has led or participated in the successful development and regulatory submission of several ophthalmic products with extensive knowledge and experience in all major ophthalmic indications and technology platforms, including sustained drug delivery to treat ocular diseases.

    Michael Burr

    Vice President of Product Development, iVeena
    Michael Burr

    Mr. Burr has over 10 years of experience in ocular drug delivery and device development. As Vice President of Product Development, he oversees the commercial development of iVeena’s pipeline. He holds master’s degrees in Biomedical Engineering and Business Administration. His training and experience have allowed him to excel within iVeena where he has developed and validated ocular drug delivery platforms with focus on improving the delivery of drugs to the back of the eye. He has led the development of iVeena’s lead product, a small molecule drug delivery implant, including formulation, GMP manufacturing, the preclinical program, regulatory, and clinical development.

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Mitchell De Long

    Mitchell A. (Mitch) deLong holds the position of vice president, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 5 INDs and 2 NDAs, with its first FDA approval coming in 2017. Aerie has grown from the initial 3-person team to over 300 employees, and went public on NASDAQ in 2013, where its current valuation is over $2 billion (US). Mitch is lead inventor on over 50 issued US patents, about half of those at Aerie, and has over 100 publications, posters and presentations. Mitch earned his PhD in Synthetic Organic and Medicinal Chemistry at Stanford University, and has two other marketed drugs to his credit.

    Peter Morgan Warren

    Medical Assessor, MHRA
    Peter Morgan Warren

    Dr Peter Morgan-Warren is a Medical Assessor at the Medicines & Healthcare products Regulatory Agency.
    After graduating in medicine from University of Oxford, Peter worked as a Medical Officer for the Royal Air Force, with clinical practice in both primary and secondary care and additional aviation medicine/administrative roles. He then went on to undertake specialist clinical training in ophthalmology in the West Midlands and was appointed as the inaugural Medical Research Council/Royal College of Ophthalmologists John Lee Fellow in 2012 for his doctoral research programme into the development of novel biotherapeutics for neuroprotection and regeneration for optic neuropathy. He was awarded his PhD from University of Birmingham in 2016.
    Peter is now a Medical Assessor at the MHRA, involved in the review and assessment of regulatory submission for national and European medicinal products, and contribution to scientific advice provision for clinical development programmes.

    Raid Alany

    Chair in Pharmaceutical Formulation and Drug Delivery, Kingston University
    Raid Alany

    Professor Raid Alany’s academic journey spans three continents; namely, Asia, Oceania and Europe. A pharmacy graduate and a registered New Zealand pharmacist; Raid received his PhD in ocular drug delivery from the University of Otago, Dunedin, New Zealand in 2001. He then became a Senior Lecturer and Head of Pharmaceutics at the School of Pharmacy, The University of Auckland in New Zealand and later joined Kingston University London where he was appointed Research Director for the School of Pharmacy and Chemistry and the Inaugural Head of School of Life Sciences, Pharmacy and Chemistry. This ‘’super’’ school is the largest in Kingston University London comprising four departments, well over 2000 students, over 100 academic staff. His research team at Kingston comprised a CARA Visiting Fellow, Leverhulme Visiting Fellow, ten PhD students and a Sparks Research Fellow working on a range of drug delivery projects; he has supervised to completion 22 Masters by Research and PhD students. Raid is an author on over 200 scientific research publications (papers and abstracts), a book and seven book chapters; he has attracted over $NZ 2M (£GBP 1M) in contestable research and enterprise funding. Professor Alany acts as an editor and serves on the editorial boards for many journals and publications. He is past president of the New Zealand Chapter of the Controlled Release Society (NZCRS) and past member of the Scientific Steering Group of the New Zealand National Eye Centre, the International Pharmaceutical Federation (FIP) and Australasian Pharmaceutical Scientists Association (APSA). He has won several awards and consults for pharmaceutical companies in New Zealand and Singapore and is an inventor on several international patents; he receives regular invitations to present at international meetings.

    Simon Chandler

    Executive Director, Clinical Development, Allergan Ltd
    Simon Chandler

    Virginia Calder

    Reader in Ocular Immunology, UCL Institute of Ophthalmology
    Virginia Calder

    Professor Calder is an immunologist with over 30 years’ experience in inflammatory eye disease research. It is well-known that immunosuppressives can be effective in arresting intraocular immune-mediated diseases but their associated side-effects can be devastating, especially for the eye, when taken long term. The focus of her team is to investigate the underlying immune mechanisms and potential novel therapeutic targets in chronic inflammatory eye diseases such as posterior uveitis, as well as blepharo, atopic and vernal keratoconjunctivitis. This involves utilizing relevant experimental models of disease and validating results with clinically well-defined donor specimens, including conjunctival tissues, aqueous humor, tear fluid, peripheral blood and serum. She has considerable expertise in determining the therapeutic efficacy of novel compounds in experimental disease models, as part of previous and ongoing research collaborations with Pharma.

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out